Hartwig Medical Foundation

Name

Hartwig Medical Foundation

Legal name

Hartwig Medical Foundation

Website

https://hartwigmedicalfoundation.nl

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Cancer Genomics Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Whole genome sequencing
• Cancer genomic diagnostics
• Clinical DNA testing
• Precision oncology services
• Cancer research database

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

1. WGS Diagnostic Testing Services: Hartwig provides whole-genome sequencing services to hospitals and healthcare providers. The organization has received a reimbursement title for WGS for certain patient groups, indicating a pathway to healthcare system reimbursement. As of January 2026, pricing was reduced to make molecular diagnostics more accessible.
2. Research Data Access: The Hartwig Medical Database is made available to researchers worldwide free of charge following approval by an independent scientific committee. This creates value through research collaborations and publications rather than direct revenue.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Hartwig Medical Foundation provides whole genome sequencing (WGS) diagnostic testing services for cancer patients through hospital partnerships, anchored by the OncoAct Complete DNA Test. The foundation operates the Hartwig Medical Database of linked genomic and clinical data from over 7,000 metastatic cancer patients, used by researchers worldwide, and runs national programs (GENAYA for young adults, GLOW for glioblastoma) that combine sequencing, AI-driven interpretation, and clinical-trial matching.

Product overview

Hartwig Medical Foundation offers a unified portfolio of whole genome sequencing services and data platforms for cancer care. The core offerings include OncoAct (WGS diagnostic service), HartwigSequencingServices (sequencing operations), and the Hartwig Medical Database (research data repository). Supporting programs include GENAYA for adolescent and young adult cancers and GLOW for glioblastoma research. Analytics tools like WiGiTS and the Hartwig Klantenportaal complete the ecosystem for clinical and research applications.

Differentiator

Problem solved

Functional benefit

Brands

• OncoAct: Complete DNA test service using Whole Genome Sequencing (WGS) for cancer patients, providing comprehensive tumor DNA analysis and treatment recommendations.
• HartwigSequencingServices.nl
• GENAYA
• GLOW (Glioblastoma Targeted Treatment Option Maximization by Whole Genome Sequencing)
• Hartwig Medical Database
• WiGiTS

Products and services

• OncoAct Complete DNA Test Comprehensive Whole Genome Sequencing diagnostic test that maps a patient's tumor DNA against a blood reference, identifies all genetic mutations, and provides actionable treatment recommendations including registered therapies and clinical-trial options. Offered to hospital physicians via the OncoAct portal for metastatic, rare, and Cancer of Unknown Primary (CUP) patients.
• Hartwig Sequencing Services Whole genome sequencing services delivering detailed genomic reports to support clinical treatment decisions, provided to hospitals and healthcare providers on a service basis.
• Hartwig Medical Database National and international database containing genomic data from over 7,000 metastatic cancer patients linked to clinical treatment outcomes, provided to approved research groups worldwide via scientific-committee review for biomarker discovery, algorithm development, and rare-cancer research.
• GENAYA Project National research initiative collecting whole genome data from 1,000 adolescent and young adult (AYA) cancer patients aged 18–39, integrated into standard AYA care pathways across 39 participating Dutch hospitals, with the goal of understanding tumor characteristics and identifying age-specific treatment options.
• GLOW Study Clinical study applying whole genome sequencing to patients with recurrent IDH-wildtype glioblastoma to identify personalized treatment options including targeted therapies and clinical trials; involves 12 Dutch hospitals and 235 enrolled patients.
• WiGiTS Analysis Tool Analytics platform for analyzing genomic data and supporting clinical decision-making in oncology care, offered as part of Hartwig's research data services.
• Hartwig Klantenportaal (Customer Portal) Digital customer portal that enables hospital partners to submit WGS analysis requests and manage workflows online, replacing previous spreadsheet-based request management.

Quantifiable outcome

• 73% of patients have at least one clinically actionable biomarker identified through WGS
• +5 more outcomes

Named customers9 records

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Partnerships

16 partnerships are on record, tiered core and major.

• RochecoreTechnology or Integration · 29 June 2026Roche launched the AXELIOS 1 sequencing platform with Hartwig as a supporting collaborator. Hartwig contributed to the development and validation of the platform for whole-genome sequencing applications in oncology research. The platform uses proprietary sequencing by expansion (SBX) technology for same-day WGS results.
• Broad Clinical LabsmajorTechnology or Integration · 29 June 2026Collaborated with Roche and Hartwig in the development and validation of the AXELIOS 1 sequencing platform, supporting research applications across oncology, genetics, and infectious diseases.
• Ultima GenomicscoreTechnology or Integration · 12 June 2026Expanded strategic collaboration where Hartwig adopted Ultima's new UG200 sequencing system powered by Solaris 2.0 technology to accelerate whole-genome sequencing implementation in oncology care. The partnership aims to validate and implement ppmSeq technology for whole-genome-informed circulating tumor DNA monitoring with single-digit part-per-million sensitivity for minimal residual disease detection. Clinical studies planned at Netherlands Cancer Institute.
• Genomic Medicine Sweden (GMS)majorStrategic or Co-development Partner · 1 June 2026Signed Memorandum of Understanding (MoU) on June 1, 2026 to formalize a strategic partnership promoting precision medicine for cancer patients. Aims to advance genomic medicine collaboration between Netherlands and Sweden.
• Netherlands Cancer Institute (NKI-AvL)coreStrategic or Co-development Partner · 12 May 2026DataNexus project initiated by NKI-AvL in collaboration with Hartwig to improve data availability by connecting clinical and genomic data. First data transfer of over 400 AYA patients completed linking Hartwig database with Netherlands Cancer Registry.
• Volta LabscoreTechnology or Integration · 26 February 2026Integration of Volta Labs' Callisto automated genomics platform with Hartwig's workflows. Hartwig presented production-scale validation data showing the platform processed thousands of patient samples with improved consistency and operational efficiency over nearly a year of deployment. Both organizations expanding their Callisto deployments.
• Prinses Máxima CentrummajorStrategic or Co-development PartnerCollaboration with Princess Máxima Center for pediatric oncology to improve molecular diagnostics techniques for children's cancer. Focus on advancing WGS applications in pediatric oncology.
• GenomeScanmajorStrategic or Co-development PartnerCollaboration for faster, better, and more affordable diagnostics. CEO Kees van den Berg has stated the collaboration is essential for GenomeScan's diagnostic operations.
• IKNL (Netherlands Cancer Registry)majorStrategic or Co-development PartnerCollaboration to link genomic data from AYA patients in the Hartwig Medical Database with clinical data from the Netherlands Cancer Registry, enabling improved research on treatment outcomes.
• Genomics EnglandmajorStrategic or Co-development PartnerInternational collaboration during GRCh38 reference genome transition to ensure data comparability. Genomics England manages the largest WGS database in the UK and coordinates similar transition efforts.
• ITCC (International Consortium for Childhood Cancer)majorStrategic or Co-development PartnerInternational consortium for childhood cancers collaborating with Hartwig on reference genome standardization to enable better international data comparison and research collaboration.
• CPCT (Center for Personalized Cancer Treatment)coreStrategic or Co-development PartnerCPCT coordinates clinical studies including DRUP and CPCT-02 that use Hartwig's WGS data. The partnership enables matching patients with targeted treatments and generating real-world evidence.
• Hartwig Medical Foundation AustraliamajorStrategic or Co-development PartnerInternational partner organization developing and maintaining open source bioinformatics tools to analyze whole genomes and transcriptomes for cancer treatment and research. Based in Sydney.
• Hartwig Medical Foundation CanadamajorStrategic or Co-development PartnerInternational partner organization extending Hartwig's global reach. Based in Toronto. Works with multidisciplinary teams of software engineers and data scientists across multiple geographic locations.
• AYA ZorgnetwerkmajorStrategic or Co-development PartnerAYA (Adolescent & Young Adult) Care Network of hospitals providing integrated care to young adults with cancer. GENAYA project integrated into standard AYA care pathways across 39 participating hospitals.
• COMPRAYA StudymajorStrategic or Co-development PartnerCollaboration with COMPRAYA study (also funded by KWF) which collects medical and psychosocial health outcomes data from AYA cancer patients, complementing GENAYA's genomic data collection.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Foundation Medicine: Roche subsidiary providing comprehensive genomic profiling of tumors including WGS/WES for oncology. Direct competitor in clinical cancer genomics with broader US commercial reach and larger pharma partnerships.
• Genomics England: UK-based organization managing the largest WGS database and delivering clinical genomic services. Hartwig collaborates with Genomics England on reference genome standardization and serves a comparable mission as a national genomics program.
• Caris Life Sciences: US molecular science company offering comprehensive tumor profiling via WES/WTS with AI-driven biomarker discovery. Comparable business model combining clinical sequencing services with proprietary database assets.
• Tempus Labs: US-based health technology company offering multi-modal genomic sequencing (including WGS) combined with AI-driven clinical decision support for oncology. Operates a large-scale clinical and molecular database analogous to Hartwig Medical Database.
• Genomic Medicine Sweden: Swedish national initiative for precision medicine with formal MoU partnership with Hartwig. Comparable mission of implementing WGS in clinical care and building national genomic data infrastructure for cancer.

Others

• The Jackson Laboratory: Non-profit biomedical research institution with significant cancer genomics and clinical genomics services. Comparable non-profit model in genomic medicine and translational oncology research.

Emerging players

• Guardant Health: Specializes in liquid biopsy and ctDNA-based genomic profiling for oncology. Comparable AI/data platform approach with extensive genomic database, focused on blood-based rather than tissue WGS.
• Personal Genome Diagnostics (PGDx): Cancer genomics company offering tissue and liquid biopsy WES-based testing with pharma services. Comparable focus on comprehensive tumor profiling with regulatory-cleared IVD kit strategy (now part of Labcorp).
• Strata Oncology: US precision oncology company offering comprehensive tumor sequencing and a learning health network model. Comparable combination of clinical WGS testing with structured data collection and trial matching.

Broad incumbents

• NeoGenomics: US-based clinical oncology laboratory offering comprehensive cancer genomic testing including NGS panels. Broader commercial lab with established US hospital network and broader test menu than WGS-only focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@hartwigmedicalfoundation
• LinkedInlinkedin.com/company/hartwig-medical-foundation
• Xx.com/hartwigmedical
• Facebookfacebook.com/HartwigMedicalFoundation

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hartwig Medical Foundation